PRISM MarketView – Bio Investor Alert

New York, N.Y., April 18, 2024 – PRISM MarketView – More than 83,000 new cases of bladder cancer are diagnosed in the US each year, and the illness is responsible for around 17,000 deaths annually. Urothelial carcinoma accounts for 90% of bladder cancers in the US and western Europe, and surgery, followed by chemotherapy or radiation is the current standard of care.

There are 24 drugs approved by the FDA for bladder cancer, but due to invasive and life-changing surgical procedures, researchers continue to pursue safer and more effective bladder-sparing treatments to improve the experience, quality of life and survival rate of patients.

Significant progress has been made in the last 12 months. In December 2023, the FDA approved Astellas Pharma’s ($ALPMF) Padcev (enfortumab vedotin-ejfv) in combination with Merck’s ($MRK) Keytruda (pembrolizumab), which represented the first advance in extending patient survival in advanced bladder cancer in almost 40 years. 

In January 2024, Australian biotechnology company, Immutep Limited ($IMMP) enrolled and safely dosed the first patient it its Phase 1 trial which will evaluate eftilagimod alpha (efti) in combination with BAVENCIO® (avelumab) in up to 30 patients with metastatic urothelial carcinoma. Efti plus BAVENCIO® is a chemotherapy-free immuno-oncology (IO) that has shown promising signals of efficacy and a favorable safety profile in advanced solid tumors.

In March 2024, Bristol Myers Squibb ($BMY) won FDA approval for Opdivo in combination with the chemotherapy drugs cisplatin and gemcitabine as a treatment for unresectable or metastatic urothelial carcinoma.

Notable performers on Friday were Q32 Bio ($QTTB) soared +21.3%, and +43.0% overall for the week, Adaptive Biotechnologies ($ADPT) finished the day up +14.9%, and PMV Pharmaceuticals ($PMVP) gained +13.3% after Jefferies Financial Group initiated coverage of the company with a buy rating and a $5.00 price target on the stock.

PRISM Headlines in Bladder Cancer 

About PRISM MarketView:

Established in 2020, PRISM MarketView is dedicated to the monitoring and analysis of small cap stocks in burgeoning sectors. We deliver up-to-the-minute financial market news, provide comprehensive investor tools and foster a dynamic investor community. Central to our offerings are proprietary indexes that observe emerging sectors, including biotech, clean energy, next-generation tech, medical devices and beyond. Visit us at prismmarketview.com and follow us on Twitter.

PRISM MarketView does not provide investment advice.

Media ContactCompany Name: Prism MarketViewEmail: [email protected] Phone: 646-863-6341Website: https://prismmarketview.com

Reply

or to participate.